X0202 SCHEDULE 13G/A 0001224962 XXXXXXXX LIVE 2 Common Stock, $0.001 par value 03/31/2026 0001750149 INHIBIKASE THERAPEUTICS, INC. 45719W205 1000 N. West Street Suite 1200 Wilmington DE 19801 Rule 13d-1(c) Perceptive Advisors LLC b DE 0 12635875 0 12635875 12635875 N 8.9 IA Joseph Edelman b X1 0 12635875 0 12635875 12635875 N 8.9 IN Perceptive Life Sciences Master Fund, Ltd. b E9 0 12635875 0 12635875 12635875 N 8.9 CO INHIBIKASE THERAPEUTICS, INC. 1000 N. West Street, Suite 1200, Wilmington, DE, 19801 The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.001 per share (the "Common Stock") of INHIBIKASE THERAPEUTICS, INC. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund") The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003 Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation. Y The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 132,032,636 outstanding shares of Common Stock as of May 1, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026, and assume the exercise of Warrants (as defined below) held by the Reporting Persons for 10,320,875 shares of Common Stock. Neither Perceptive Advisors nor Mr. Edelman directly holds any Common Stock. The Master Fund directly holds (i) 2,315,000 shares of Common Stock, (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase 790,000 shares of Common Stock at an exercise price of $0.001 per share, (iii) common warrants to purchase 3,357,211 shares of Common Stock at an exercise price of $1.37 per share, and (iv) common warrants to purchase 6,173,664 shares of Common Stock at an exercise price of $1.49 per share (together with the Pre-Funded Warrants, the "Warrants"). The terms of the Warrants provide that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding. As of the date hereof, this limitation permits the Reporting Persons to exercise Warrants for up to 10,320,875 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors. Perceptive Advisors: 8.9% Mr. Edelman: 8.9% Master Fund: 8.9% Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 Perceptive Advisors: 12,635,875 Mr. Edelman: 12,635,875 Master Fund: 12,635,875 Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 Perceptive Advisors: 12,635,875 Mr. Edelman: 12,635,875 Master Fund: 12,635,875 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Perceptive Advisors LLC /s/ Joseph Edelman 05/15/2026 Joseph Edelman /s/ Joseph Edelman 05/15/2026 Perceptive Life Sciences Master Fund, Ltd. /s/ Joseph Edelman 05/15/2026